Literature DB >> 30545847

CRISPR-mediated activation of a promoter or enhancer rescues obesity caused by haploinsufficiency.

Navneet Matharu1,2, Sawitree Rattanasopha1,2,3, Serena Tamura1,2, Lenka Maliskova1,2, Yi Wang4, Adelaide Bernard4, Aaron Hardin1,2, Walter L Eckalbar1,2, Christian Vaisse4, Nadav Ahituv5,2.   

Abstract

A wide range of human diseases result from haploinsufficiency, where the function of one of the two gene copies is lost. Here, we targeted the remaining functional copy of a haploinsufficient gene using CRISPR-mediated activation (CRISPRa) in Sim1 and Mc4r heterozygous mouse models to rescue their obesity phenotype. Transgenic-based CRISPRa targeting of the Sim1 promoter or its distant hypothalamic enhancer up-regulated its expression from the endogenous functional allele in a tissue-specific manner, rescuing the obesity phenotype in Sim1 heterozygous mice. To evaluate the therapeutic potential of CRISPRa, we injected CRISPRa-recombinant adeno-associated virus into the hypothalamus, which led to reversal of the obesity phenotype in Sim1 and Mc4r haploinsufficient mice. Our results suggest that endogenous gene up-regulation could be a potential strategy to treat altered gene dosage diseases.
Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30545847      PMCID: PMC6570489          DOI: 10.1126/science.aau0629

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  81 in total

1.  In Vivo Silencing/Overexpression of lncRNAs by CRISPR/Cas System.

Authors:  Marianna Vitiello; Laura Poliseno; Pier Paolo Pandolfi
Journal:  Methods Mol Biol       Date:  2021

2.  Exons as units of phenotypic impact for truncating mutations in autism.

Authors:  Andrew H Chiang; Jonathan Chang; Jiayao Wang; Dennis Vitkup
Journal:  Mol Psychiatry       Date:  2020-10-27       Impact factor: 15.992

3.  Cln3-mutations underlying juvenile neuronal ceroid lipofuscinosis cause significantly reduced levels of Palmitoyl-protein thioesterases-1 (Ppt1)-protein and Ppt1-enzyme activity in the lysosome.

Authors:  Abhilash P Appu; Maria B Bagh; Tamal Sadhukhan; Avisek Mondal; Sydney Casey; Anil B Mukherjee
Journal:  J Inherit Metab Dis       Date:  2019-05-14       Impact factor: 4.982

Review 4.  Functional genomics links genetic origins to pathophysiology in neurodegenerative and neuropsychiatric disease.

Authors:  Brie Wamsley; Daniel H Geschwind
Journal:  Curr Opin Genet Dev       Date:  2020-07-04       Impact factor: 5.578

5.  A Chromatin Accessibility Atlas of the Developing Human Telencephalon.

Authors:  Eirene Markenscoff-Papadimitriou; Sean Whalen; Pawel Przytycki; Reuben Thomas; Fadya Binyameen; Tomasz J Nowakowski; Arnold R Kriegstein; Stephan J Sanders; Matthew W State; Katherine S Pollard; John L Rubenstein
Journal:  Cell       Date:  2020-06-30       Impact factor: 41.582

Review 6.  CRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV Vectors.

Authors:  Dan Wang; Feng Zhang; Guangping Gao
Journal:  Cell       Date:  2020-04-02       Impact factor: 41.582

Review 7.  Next-generation regulatory T cell therapy.

Authors:  Leonardo M R Ferreira; Yannick D Muller; Jeffrey A Bluestone; Qizhi Tang
Journal:  Nat Rev Drug Discov       Date:  2019-09-20       Impact factor: 84.694

8.  Amelioration of an Inherited Metabolic Liver Disease through Creation of a De Novo Start Codon by Cytidine Base Editing.

Authors:  Lei Yang; Liren Wang; Yanan Huo; Xi Chen; Shuming Yin; Yaqiang Hu; Xiaohui Zhang; Rui Zheng; Hongquan Geng; Honghui Han; Xueyun Ma; Meizhen Liu; Haibo Li; Weishi Yu; Mingyao Liu; Jun Wang; Dali Li
Journal:  Mol Ther       Date:  2020-05-07       Impact factor: 11.454

Review 9.  Neurobiological functions of transcriptional enhancers.

Authors:  Alex S Nord; Anne E West
Journal:  Nat Neurosci       Date:  2019-11-18       Impact factor: 24.884

Review 10.  CRISPR-Based Synthetic Transcription Factors In Vivo: The Future of Therapeutic Cellular Programming.

Authors:  Matthew Pandelakis; Elizabeth Delgado; Mo R Ebrahimkhani
Journal:  Cell Syst       Date:  2020-01-22       Impact factor: 10.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.